PARP overactivation in neurological disorders
- PMID: 33768369
- DOI: 10.1007/s11033-021-06285-1
PARP overactivation in neurological disorders
Abstract
Poly (ADP-ribose) polymerases (PARPs) constitute a family of enzymes associated with divergent cellular processes that are not limited to DNA repair, chromatin organization, genome integrity, and apoptosis but also found to play a crucial role in inflammation. PARPs mediate poly (ADP-ribosylation) of DNA binding proteins that is often responsible for chromatin remodeling thereby ensure effective repairing of DNA stand breaks although during the conditions of severe genotoxic stress PARPs direct the cell fate towards apoptotic events. Recent discoveries have pushed PARPs into the spotlight as targets for treating cancer, metabolic, inflammatory and neurological disorders. Of note, PARP-1 is the most abundant isoform of PARPs (18 member super family) which executes more than 90% of PARPs functions. Since oxidative/nitrosative stress actuated PARP-1 is linked to vigorous DNA damage and wide spread provocative inflammatory response that underlie the aetiopathogenesis of different neurological disorders, possibility of developing PARP-1 inhibitors as plausible neurotherapeutic agents attracts considerable research interest. This review outlines the recent advances in PARP-1 biology and examines the capability of PARP-1 inhibitors as treatment modalities in intense and interminable diseases of neuronal origin.
Keywords: Neuroinflammation; Neurological disorders; PARP-1; PARP1 inhibitors.
Similar articles
-
Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.Methods Enzymol. 2006;409:493-510. doi: 10.1016/S0076-6879(05)09029-4. Methods Enzymol. 2006. PMID: 16793420
-
Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases.Front Med (Lausanne). 2022 Nov 10;9:1062432. doi: 10.3389/fmed.2022.1062432. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36438061 Free PMC article. Review.
-
PARPs and PAR as novel pharmacological targets for the treatment of stress granule-associated disorders.Biochem Pharmacol. 2019 Sep;167:64-75. doi: 10.1016/j.bcp.2019.05.019. Epub 2019 May 15. Biochem Pharmacol. 2019. PMID: 31102582 Review.
-
[Role of PARP and protein poly-ADP-ribosylation process in regulation of cell functions].Ukr Biokhim Zh (1999). 2011 Nov-Dec;83(6):5-34. Ukr Biokhim Zh (1999). 2011. PMID: 22364016 Review. Ukrainian.
-
Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.Neurochem Int. 2007 Jun;50(7-8):954-8. doi: 10.1016/j.neuint.2006.11.010. Epub 2007 Jan 12. Neurochem Int. 2007. PMID: 17222947 Review.
Cited by
-
Recent Advances in Biomolecular Patho-Mechanistic Pathways behind the Development and Progression of Diabetic Neuropathy.Biomedicines. 2024 Jun 23;12(7):1390. doi: 10.3390/biomedicines12071390. Biomedicines. 2024. PMID: 39061964 Free PMC article. Review.
-
Poly ADP-Ribose Polymerase-1 inhibition by 3-aminobenzamide recuperates HEI-OC1 auditory hair cells from blast overpressure-induced cell death.Front Cell Dev Biol. 2023 Mar 6;11:1047308. doi: 10.3389/fcell.2023.1047308. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36949771 Free PMC article.
-
An ADPRS variant disrupts ARH3 stability and subcellular localization in children with neurodegeneration and respiratory failure.HGG Adv. 2025 Jan 9;6(1):100386. doi: 10.1016/j.xhgg.2024.100386. Epub 2024 Nov 22. HGG Adv. 2025. PMID: 39580621 Free PMC article.
-
Proteins Associated with Neurodegenerative Diseases: Link to DNA Repair.Biomedicines. 2024 Dec 11;12(12):2808. doi: 10.3390/biomedicines12122808. Biomedicines. 2024. PMID: 39767715 Free PMC article. Review.
-
Cannabidiol and Beta-Caryophyllene Combination Attenuates Diabetic Neuropathy by Inhibiting NLRP3 Inflammasome/NFκB through the AMPK/sirT3/Nrf2 Axis.Biomedicines. 2024 Jun 28;12(7):1442. doi: 10.3390/biomedicines12071442. Biomedicines. 2024. PMID: 39062016 Free PMC article.
References
-
- Chambon P, Weill J, Mandel P (1963) Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39–43 - PubMed
-
- Amé JC, Spenlehauer C, de Murcia G (2004) The PARP superfamily. BioEssays 26:882–893 - PubMed
-
- Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS et al (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175:192–222 - PubMed
-
- de Murcia G, De Murcia JM (1994) Poly (ADP-ribose) polymerase:a molecular nick sensor. Trends Biochem Sci 19:172–176 - PubMed
-
- Berger N, Berger S, Catino D, Petzold S, Robins R (1985) Modulation of nicotinamide adenine dinucleotide and poly (adenosine diphosphoribose) metabolism by the synthetic. J Clin Investig 75:702–709 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous